Ginkgo Bioworks, a horizontal platform for cell programming, has acquired biotechnology company Zymergen.
This deal combines two organizations that believe biology can transform various industries like manufacturing.
“We have always had incredible respect for the Zymergen team and the strength of the technologies that they built for cell programming,” said Jason Kelly, CEO of Ginkgo Bioworks. “We can’t wait to welcome Zymergen’s technical teams, who will support our scaling objectives.”
Allen & Company LLC is serving as financial advisor, and Ropes & Gray LLP is acting as legal advisor to Ginkgo. Cowen and Company LLC is serving as financial advisor, and Freshfields Bruckhaus Deringer US LLP is acting as legal advisor to Zymergen.